论文部分内容阅读
肺癌是所有恶性肿瘤病死率中增长最快,危害最大的恶性肿瘤之一。由于就诊时多为晚期,即使经手术、化疗和放疗后患者的生存质量仍难以改变,且预后极差,5年生存率小于15%。近年来肿瘤生物疗法作为辅助疗法,可消除患者体内残存的肿瘤细胞,针对肺癌发病机制的基因治疗,有望改善患者的生存质量和预后,为肺癌的临床治疗开避了新途径。本文就肺癌生物治疗的研究进展作一综述。
Lung cancer is one of the most rapidly increasing and most harmful malignancies among all malignant tumors. Due to the late stage of treatment, the quality of life of patients remains difficult to change even after surgery, chemotherapy and radiotherapy, and the prognosis is very poor. The 5-year survival rate is less than 15%. In recent years, tumor biological therapy as an adjuvant therapy can eliminate residual tumor cells in patients with the body, the gene therapy for the pathogenesis of lung cancer is expected to improve the quality of life of patients and prognosis for the clinical treatment of lung cancer to avoid a new way. This article reviews the research progress of biological treatment of lung cancer.